CliffBio
biologic

Hizentra

Immune Globulin Subcutaneous (Human), 20% Liquid

Loss of exclusivityMarch 2022projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameHizentra
Active ingredientImmune Globulin Subcutaneous (Human), 20% Liquid
Strength4G/20ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2010
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hizentra patent cliff — loss of exclusivity March 2022 | CliffBio